Galectin Therapeutics Inc.

US$3.14As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GALTHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 15.83%
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.50
PE TTM —
TSR TTM (45.96%)
Mkt cap US$316.7M
ROIC (162.96%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.32
5.84%
3.88%
Hold 3|10|3|12|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.03
0.03
0.03
0.03
11.30%
(2.42%)
7.08%
(1.65%)
Revenue$M
29.35
28.60
29.42
29.10
11.19%
6.73%
4.23%
(2.27%)
Peers (US$316.7M)
Cap (US$)
PE
313.9M
—
317.3M
—
Capital
TTM
5Y
10Y
Leveragex
1.538
—
—
EBIT/Intx
1.973
0.766
0.827
Own earn%
8.37
149.38
152.19
Sh yield%
37.23
32.27
32.77
Owners
Insiders/Inst%
8.21
70.64
Short interest%
1.13
SBC / revenue%
2.29
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
22–31
$1 testx
0.0
Incr. ROIC%
0